The humanized antibody tiragolumab targeting T-cell immunoreceptor with Ig and ITIM domains, TIGIT is an immune checkpoint inhibitor that blocks the binding of TIGIT to its ligand CD155, thereby enhancing T-cell and NK-cell anti-tumor activity. This evidence concerns the gene TIGIT and neoplasm.